NZ706154A - 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy - Google Patents
1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapyInfo
- Publication number
- NZ706154A NZ706154A NZ706154A NZ70615411A NZ706154A NZ 706154 A NZ706154 A NZ 706154A NZ 706154 A NZ706154 A NZ 706154A NZ 70615411 A NZ70615411 A NZ 70615411A NZ 706154 A NZ706154 A NZ 706154A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- phenyl
- imidazo
- yloxy
- pyrazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- IBCZSSWQZVYRBN-UHFFFAOYSA-N 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[2-fluoro-4-[(1-methyl-2-oxo-3h-imidazo[4,5-b]pyridin-7-yl)oxy]phenyl]urea Chemical compound C1=CN=C2NC(=O)N(C)C2=C1OC(C=C1F)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=CC=C1 IBCZSSWQZVYRBN-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 2
- VYUIFWUMNSBCAH-UHFFFAOYSA-N 1-(5-tert-butyl-2-phenylpyrazol-3-yl)-3-[4-[(1-methyl-2-oxo-3h-imidazo[4,5-b]pyridin-7-yl)oxy]naphthalen-1-yl]urea Chemical compound C1=CN=C2NC(=O)N(C)C2=C1OC(C1=CC=CC=C11)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=CC=C1 VYUIFWUMNSBCAH-UHFFFAOYSA-N 0.000 abstract 1
- 206010004593 Bile duct cancer Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 201000010208 Seminoma Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000026900 bile duct neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000006990 cholangiocarcinoma Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30008510P | 2010-02-01 | 2010-02-01 | |
| NZ60108511A NZ601085A (en) | 2010-02-01 | 2011-01-27 | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ706154A true NZ706154A (en) | 2016-09-30 |
Family
ID=43629408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ706154A NZ706154A (en) | 2010-02-01 | 2011-01-27 | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| NZ60108511A NZ601085A (en) | 2010-02-01 | 2011-01-27 | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ60108511A NZ601085A (en) | 2010-02-01 | 2011-01-27 | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US8815896B2 (enExample) |
| EP (1) | EP2531502B1 (enExample) |
| JP (2) | JP5760010B2 (enExample) |
| CN (2) | CN104945401B (enExample) |
| AU (1) | AU2011209586B2 (enExample) |
| BR (1) | BR112012018415A2 (enExample) |
| CA (1) | CA2786834C (enExample) |
| DK (1) | DK2531502T3 (enExample) |
| ES (1) | ES2469367T3 (enExample) |
| NZ (2) | NZ706154A (enExample) |
| PL (1) | PL2531502T3 (enExample) |
| WO (1) | WO2011092469A1 (enExample) |
| ZA (1) | ZA201205181B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| EP4663636A2 (en) | 2014-03-07 | 2025-12-17 | BioCryst Pharmaceuticals, Inc. | Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors |
| WO2017144877A1 (en) | 2016-02-23 | 2017-08-31 | Cancer Research Technology Limited | Dietary product devoid of at least two non essential amino acids |
| AU2018363295A1 (en) | 2017-11-13 | 2020-07-02 | Cancer Research Technology Ltd | Dietary product |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| GB201818649D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| GB201818651D0 (en) | 2018-11-15 | 2019-01-02 | Univ Sheffield | Compounds |
| GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| WO2021013712A1 (en) | 2019-07-19 | 2021-01-28 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
| JP2023530235A (ja) | 2020-06-03 | 2023-07-14 | フェス・セラピューティクス，インコーポレーテッド | 個別化された処置方法のための製剤 |
| WO2021247923A1 (en) | 2020-06-04 | 2021-12-09 | Faeth Therapeutics, Inc. | Personalized methods of treating cancer |
| EP4029501A1 (en) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells |
| CN113189089B (zh) * | 2021-03-19 | 2022-05-17 | 四川轻化工大学 | 一种臭氧检测试剂及其制备装置和制备方法 |
| GB202208347D0 (en) | 2022-06-07 | 2022-07-20 | Univ Court Univ Of Glasgow | Targets for cancer therapy |
| GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
| GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
| WO2025229029A1 (en) | 2024-04-30 | 2025-11-06 | Gorgoulis Vassilis G | Conjugate of a senotherapeutic moiety and a lipid-targeting moiety |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4082845A (en) | 1977-04-25 | 1978-04-04 | Merck & Co., Inc. | 3-(1-Piperazinyl)-pyrido[2,3-b]pyrazines |
| JPS5665863U (enExample) | 1979-10-25 | 1981-06-02 | ||
| JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
| JPS625888Y2 (enExample) | 1980-08-14 | 1987-02-10 | ||
| JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| AU701568B2 (en) | 1994-09-22 | 1999-02-04 | Licentia Ltd | Promoter for the receptor tyrosine kinase, tie |
| CA2262403C (en) | 1995-07-31 | 2011-09-20 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| KR100567649B1 (ko) | 1996-09-25 | 2006-04-05 | 아스트라제네카 유케이 리미티드 | 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체 |
| US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
| KR100547929B1 (ko) | 1997-09-26 | 2006-02-02 | 젠타리스 게엠베하 | 세린/트레오닌 단백질 키나제 기능을 조절하기 위한 아자벤즈이미다졸계 화합물, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| CA2350234A1 (en) | 1999-01-07 | 2000-07-13 | Alexander James Bridges | Treatment of asthma with mek inhibitors |
| AU3475900A (en) | 1999-01-29 | 2000-08-18 | University Of Akron, The | Polyimides used as microelectronic coatings |
| CN1373660A (zh) | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
| AR029423A1 (es) | 1999-12-21 | 2003-06-25 | Sugen Inc | Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| EP1341771A2 (en) | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| KR20020096367A (ko) | 2001-06-19 | 2002-12-31 | 주식회사 티지 바이오텍 | 관절염 예방 또는 치료제 및 그것의 스크리닝 방법 |
| US6916814B2 (en) * | 2001-07-11 | 2005-07-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
| EP1456364B1 (en) | 2001-12-21 | 2011-03-23 | The Wellcome Trust | Mutations in the b-raf gene |
| WO2003068223A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| TW200406374A (en) * | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| JP4335136B2 (ja) | 2002-08-09 | 2009-09-30 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
| WO2004083458A1 (en) | 2003-03-20 | 2004-09-30 | Universite Catholique De Louvain | Medical use of ras antagonists for the treatment of capillary malformation |
| MXPA05013349A (es) | 2003-06-13 | 2006-03-09 | Novartis Ag | Derivados de 2-amino-pirimidina como inhibidores de quinasa raf. |
| WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| EP1789399A1 (en) | 2004-08-31 | 2007-05-30 | AstraZeneca AB | Quinazolinone derivatives and their use as b-raf inhibitors |
| BRPI0518126A (pt) | 2004-10-15 | 2008-10-28 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anti-cáncer em um animal de sangue quente, e para tratar uma doença ou condição |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| GB0428082D0 (en) | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ， エルエルシー | 酵素モジュレータ及び治療 |
| WO2007059202A2 (en) | 2005-11-15 | 2007-05-24 | Bayer Healthcare Ag | Pyrazolyl urea derivatives useful in the treatment of cancer |
| US20110195110A1 (en) * | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
| CA2632512A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| EP2013207B1 (en) | 2006-04-26 | 2012-04-25 | Cancer Research Technology Limited | Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| WO2008044688A1 (en) | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| US7790756B2 (en) * | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| BRPI0814685A2 (pt) | 2007-07-10 | 2019-09-24 | Neurin Pharmaceuticals 1991 Ltd | variantes com splicing de cd44 em doenças neurodegenerativas |
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| KR20110070887A (ko) | 2008-10-02 | 2011-06-24 | 레스피버트 리미티드 | Ｐ38 엠에이피 키나제 억제제 |
| WO2010067131A1 (en) | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| WO2011004276A1 (en) | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| EP2470898A4 (en) | 2009-08-24 | 2013-03-13 | Genentech Inc | DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT IN DETECTION OF K-RAS MUTATIONS AND MEASURING RTK EXPRESSION LEVELS |
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| JP5760010B2 (ja) | 2010-02-01 | 2015-08-05 | キャンサー・リサーチ・テクノロジー・リミテッド | １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用 |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| US9024041B2 (en) | 2010-04-08 | 2015-05-05 | Respivert Ltd. | P38 MAP kinase inhibitors |
| WO2011124923A2 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| JP5973426B2 (ja) | 2010-06-17 | 2016-08-23 | レスピバート・リミテツド | Ｐ３８ｍａｐｋ阻害剤を含む呼吸器用製剤 |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| WO2012008564A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| WO2012149547A1 (en) | 2011-04-28 | 2012-11-01 | Duke University | Methods of treating hemoglobinopathies |
| EA025266B1 (ru) | 2011-06-23 | 2016-12-30 | Ваймет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
| AU2012302106B2 (en) | 2011-09-01 | 2015-04-09 | Novartis Ag | Use of organic compound for the treatment of noonan syndrome |
| PT2763984T (pt) | 2011-10-03 | 2016-07-25 | Respivert Ltd | 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureias como inibidores da map cinase p38 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
| WO2014140582A1 (en) | 2013-03-14 | 2014-09-18 | Respivert Limited | Kinase inhibitors |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| US9481648B2 (en) | 2013-04-02 | 2016-11-01 | Respivert Limited | Kinase inhibitors |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN113717162A (zh) | 2013-12-20 | 2021-11-30 | 奥苏拉收购有限公司 | 用作激酶抑制剂的脲衍生物 |
| DK3357919T3 (da) | 2014-02-14 | 2020-02-17 | Respivert Ltd | Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser |
| MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
| EP3201189A1 (en) | 2014-10-01 | 2017-08-09 | Respivert Limited | N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors |
-
2011
- 2011-01-27 JP JP2012550510A patent/JP5760010B2/ja not_active Expired - Fee Related
- 2011-01-27 NZ NZ706154A patent/NZ706154A/en not_active IP Right Cessation
- 2011-01-27 US US13/520,613 patent/US8815896B2/en not_active Expired - Fee Related
- 2011-01-27 CA CA2786834A patent/CA2786834C/en not_active Expired - Fee Related
- 2011-01-27 CN CN201510266876.5A patent/CN104945401B/zh not_active Expired - Fee Related
- 2011-01-27 NZ NZ60108511A patent/NZ601085A/en not_active IP Right Cessation
- 2011-01-27 WO PCT/GB2011/000106 patent/WO2011092469A1/en not_active Ceased
- 2011-01-27 CN CN201180008030.1A patent/CN102906090B/zh not_active Expired - Fee Related
- 2011-01-27 PL PL11701856T patent/PL2531502T3/pl unknown
- 2011-01-27 BR BR112012018415-6A patent/BR112012018415A2/pt not_active Application Discontinuation
- 2011-01-27 ES ES11701856.4T patent/ES2469367T3/es active Active
- 2011-01-27 AU AU2011209586A patent/AU2011209586B2/en not_active Ceased
- 2011-01-27 DK DK11701856.4T patent/DK2531502T3/da active
- 2011-01-27 EP EP11701856.4A patent/EP2531502B1/en active Active
-
2012
- 2012-07-12 ZA ZA2012/05181A patent/ZA201205181B/en unknown
-
2014
- 2014-07-15 US US14/331,653 patent/US9120789B2/en not_active Expired - Fee Related
-
2015
- 2015-06-08 JP JP2015115366A patent/JP5956653B2/ja not_active Expired - Fee Related
- 2015-07-30 US US14/813,658 patent/US9439893B2/en not_active Expired - Fee Related
-
2016
- 2016-09-01 US US15/254,103 patent/US9820976B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5760010B2 (ja) | 2015-08-05 |
| ES2469367T3 (es) | 2014-06-18 |
| NZ601085A (en) | 2015-04-24 |
| AU2011209586B2 (en) | 2016-01-21 |
| JP5956653B2 (ja) | 2016-07-27 |
| DK2531502T3 (da) | 2014-05-19 |
| US20140357663A1 (en) | 2014-12-04 |
| PL2531502T3 (pl) | 2014-08-29 |
| ZA201205181B (en) | 2013-09-25 |
| CN104945401B (zh) | 2017-09-05 |
| CN102906090A (zh) | 2013-01-30 |
| US8815896B2 (en) | 2014-08-26 |
| JP2015180675A (ja) | 2015-10-15 |
| AU2011209586A1 (en) | 2012-08-09 |
| EP2531502A1 (en) | 2012-12-12 |
| JP2013518089A (ja) | 2013-05-20 |
| EP2531502B1 (en) | 2014-04-02 |
| CN102906090B (zh) | 2015-06-24 |
| WO2011092469A1 (en) | 2011-08-04 |
| WO2011092469A8 (en) | 2012-08-16 |
| US9439893B2 (en) | 2016-09-13 |
| US9820976B2 (en) | 2017-11-21 |
| CA2786834C (en) | 2018-10-16 |
| US20170079963A1 (en) | 2017-03-23 |
| US20120283288A1 (en) | 2012-11-08 |
| BR112012018415A2 (pt) | 2020-08-04 |
| CA2786834A1 (en) | 2011-04-08 |
| US9120789B2 (en) | 2015-09-01 |
| US20160030405A1 (en) | 2016-02-04 |
| CN104945401A (zh) | 2015-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ706154A (en) | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy | |
| IL245062B (en) | History of 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-h4-pyrido[3,2-b]pyrazine-8 -Il)oxy]phenyl]urea as raf inhibitors for cancer treatment | |
| EP4458418A3 (en) | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | |
| AU2015205914B2 (en) | 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections | |
| MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
| GEP20125469B (en) | Inhibitors of akt activity | |
| EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
| MX340533B (es) | Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| WO2014188178A9 (en) | Polymyxin derivatives and their use in combination therapy together with different antibiotics | |
| PH12014501925A1 (en) | Nitrogen-containing aromatic heterocyclic compound | |
| CL2008000785A1 (es) | Compuestos derivados de 4-((7,7-difluoro-5-metil-6-oxo-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-2-il)amino)-3-metoxibenzamida; compuesto intermediario; composicion farmaceutica, utiles para tratar el cancer. | |
| EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
| NZ615270A (en) | Phosphoramidate derivatives of 5 - fluoro - 2 ‘ - deoxyuridine for use in the treatment of cancer | |
| HUE049886T2 (hu) | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra | |
| UA104731C2 (ru) | Ингибиторы р38 мар-киназ | |
| MY188911A (en) | Methods of treating bladder cancer | |
| UA100540C2 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| WO2006044826A3 (en) | Thiophens and their use as anti-tumor agents | |
| MX2013007268A (es) | Activadores de pkm2 bicíclicos. | |
| PH12014502294A1 (en) | Triazolo compounds as pde10 inhibitors | |
| GEP20156346B (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
| WO2010027424A3 (en) | 9-substituted phenanthrene based tylophorine derivatives | |
| EP4585267A3 (en) | Coumarin based hsp90 inhibitors with urea and ether substituents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 JAN 2018 BY HENRY HUGHES IP LIMITED Effective date: 20170327 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2019 BY MEWBURN ELLIS LLP Effective date: 20180119 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2020 BY MEWBURN ELLIS LLP Effective date: 20190117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 JAN 2021 BY MEWBURN ELLIS LLP Effective date: 20200121 |
|
| LAPS | Patent lapsed |